Home › Funds › Prosight Management, LP › NKTR
Prosight Management, LP position in NKTR
NEKTAR THERAPEUTICS · Health Care
Prosight Management, LP reported holding 785,000 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$47.5M, representing 9.22% of its reported portfolio and ranking #4 among its reported holdings. Prosight Management, LP has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's NKTR position evolved
Prosight Management, LP first disclosed a stake in NKTR in Q4 2025 at 554,633 shares (US$23.4M). The position peaked in Q2 2026 at 810,000 shares, worth US$56.5M. Across 4 filings, Prosight Management, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 785,000 shares valued at US$47.5M — a reduction of -25,000 shares quarter over quarter.. Notable position changes include a 33% increase in Q1 2026 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 554.63K | $23.45M | New |
| Q1 2026 | 735.00K | $52.88M | Add |
| Q2 2026 | 810.00K | $56.55M | Add |
| Q3 2026 | 785.00K | $47.53M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- 22NW, LP 281.12K sh · $17.02M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
- Bronte Capital Management Pty Ltd. 202.06K sh · $12.23M · Q3 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held NKTR?
Prosight Management, LP has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Prosight Management, LP's current position in NKTR?
As of Q3 2026, Prosight Management, LP holds 785.00K shares of NKTR (NEKTAR THERAPEUTICS), valued at $47.53M, representing 9.22% of its reported portfolio and ranking #4.
Has Prosight Management, LP been buying or selling NKTR?
In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in NKTR. The position peaked in Q2 2026 at 810.00K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.